MENDLEIN JOHN 4
4 · FATE THERAPEUTICS INC · Filed Mar 11, 2022
Insider Transaction Report
Form 4
MENDLEIN JOHN
Director
Transactions
- Exercise/Conversion
Common Stock
2022-03-10$1.63/sh+31,562$51,446→ 191,017 total - Sale
Common Stock
2022-03-10$34.73/sh−19,493$676,992→ 171,524 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-03-10−31,562→ 0 totalExercise: $1.63Exp: 2022-03-12→ Common Stock (31,562 underlying) - Sale
Common Stock
2022-03-10$35.48/sh−12,069$428,208→ 159,455 total
Footnotes (4)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021.
- [F2]Represents the weighted average sale price of the shares sold from $34.12 to $35.11 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of he Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 3.
- [F3]Represents the weighted average sale price of the shares sold from $35.13 to $35.75 per share.
- [F4]This option is fully vested.